Building on this, Merck has been working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology combinations, including Keytruda with LAG3 and CTLA-4 inhibitors. In partnership with Moderna, Merck is developing a personalized mRNA-based cancer vaccine, intismeran autogene (V940/mRNA-4157), in combination with Keytruda. The regimen is currently being evaluated in pivotal phase III studies for earlier-stage and adjuvant NSCLC as well as adjuvant melanoma. Merck ...

Core Insights - Tempus AI, Inc. and Merck have announced an expanded multi-year collaboration to enhance the discovery and development of precision medicine biomarkers, particularly in oncology [1][2] - The partnership aims to leverage Tempus' de-identified multimodal datasets and advanced AI capabilities to improve patient outcomes and accelerate the development of candidate therapies [2][3] Company Overview - Tempus is a technology company focused on advancing precision medicine through AI applications in healthcare, boasting one of the largest libraries of multimodal data [4] - The company provides AI-enabled solutions to physicians, aiming to personalize patient care and facilitate the discovery and development of optimal therapeutics [4] Collaboration Details - Under the agreement, Merck will utilize Tempus' Lens Platform and Workspaces environment, which is powered by a significant GPU infrastructure, to conduct complex analyses on multimodal datasets [2] - The collaboration is expected to enhance Merck's precision oncology strategy by applying AI/ML capabilities to discover novel biomarkers and inform drug combinations in their early pipeline [3]

Palisade Bio (NasdaqCM:PALI) FY Conference March 02, 2026 03:10 PM ET Company ParticipantsJ.D. Finley - CEOMitch Jones - President and Chief Medical OfficerTara Bancroft - VP of Health CareTara BancroftHi, I'm Tara Bancroft. I'm one of the Senior Biotech Analysts at TD Cowen. I wanna thank you guys all for coming to TD Cowen's 46th Annual Healthcare Conference. Our next session is a presentation from Palisade Bio. From Palisade we have J.D. Finley, the CEO, and Mitch Jones, the CMO. Thank you guys both for ...

She also cited continued growth in other segments, including 13% growth in vaccines and 9% growth in nutritional specialties for the quarter. Bendheim said the strong first half gave the company confidence to raise guidance for revenue, EBITDA, and adjusted net income, and she described investor feedback as “very positive.”Within MFAs, Bendheim noted the legacy MFA business declined 5% in the quarter due to the timing of an order from a large customer for an API product. She said that, normalized for the ti ...

Core Insights - Arcus Biosciences aims to establish casdatifan as a "best-in-class" HIF-2α inhibitor for clear cell renal cell carcinoma (ccRCC) with updated clinical data showing promising efficacy compared to belzutifan [3][5][14] Clinical Data and Development - Updated analysis from the ARC-20 study indicates a median progression-free survival (PFS) of 15.1 months for casdatifan monotherapy, significantly longer than the 5.6-month PFS reported for belzutifan in similar late-line settings [1][2][5] - The confirmed overall response rate (ORR) for casdatifan has risen to 45% in the latest data [5] - The Phase III PEAK-1 trial is actively enrolling patients, comparing casdatifan plus cabozantinib against cabozantinib alone, with a goal to complete enrollment by year-end [6][10] Financial Overview - Arcus ended Q4 with $1.0 billion in cash, following a $288 million financing, and expects to fund operations into at least the second half of 2028 [4][17][18] - The company projects 2026 GAAP revenue between $45 million and $55 million, with anticipated decreases in operating expenses [18] Market Opportunity - The renal cell carcinoma (RCC) market is projected to exceed $10 billion annually, with expectations to grow to $13 billion by 2030, positioning casdatifan as a key player in this competitive landscape [14][15] - Arcus estimates peak sales for casdatifan could reach $2.5 billion in the IO-experienced setting and $3 billion or more in the first-line setting [15] Immunology Pipeline - Arcus is developing an inflammation and immunology (I&I) portfolio, with plans to enter clinical trials for a MRGPRX2 antagonist and a selective TNF receptor 1 inhibitor [16]

Company Overview - Erasca, Inc. is a clinical-stage biotech company focused on RAS/MAPK-driven cancers, addressing a significant unmet medical need globally [1] - The company currently has no commercially approved products, resulting in zero revenue, and its valuation reflects early-stage risk rather than fundamentals [2] Clinical Development - Erasca has achieved IND clearance for its two lead assets, ERAS-0015 and ERAS-4001, advancing both into Phase 1 monotherapy trials, with data expected in 2026 [2] - The company maintains a cash runway into H2 2028, potentially extending to 2029 following recent offerings, while net losses have narrowed and operating expenses declined [2] Competitive Landscape - The assets of Erasca show technically differentiated profiles with potential best-in-class RAS-targeting and strong preclinical potency, but the competitive landscape is crowded with larger biotechs and pharma pursuing similar targets [3] - Intellectual property protections, including a U.S. composition-of-matter patent for ERAS-0015 through 2043, provide some advantage, though the firm lacks a wide structural moat until clinical approval and market adoption [3] Management and Financial Strategy - The management team is highly experienced and strategically focused, having prudently extended the cash runway, but future equity raises are likely, creating dilution risk [4] - Key catalysts for the company include the release of Phase 1 data in 2026, potential strategic partnerships, and licensing opportunities [4] Investment Considerations - Erasca represents a high-risk, high-reward investment with significant binary outcomes tied to clinical trial results and funding conditions [4][6]

Group 1 - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck from 2009 to 2013 and has experience in biotech startups including Theravance and Aspira [1] - Brendan is a co-founder of 1200 Pharma, which spun out of Caltech and received significant investment in the 8 figures [1] Group 2 - Brendan remains an avid investor focused on market trends, particularly in biotechnology stocks [1]

Merck to lay off around 150 employees at US site amid slump in Gardasil sales | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo [Purchase Licensing Rights, opens new tab]- Companies[Merck & Co Inc]FollowFeb 27 (Reuters) - Merck [(MRK.N), opens new tab] will lay off about 150 employees across its fa ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. These late-breaking data will. ...

Dr. Elias Zerhouni, Vice Chairman and President, said the post-transaction remaining BioReference operations represented approximately $300 million in revenue in 2025. He said testing volume in the fourth quarter, excluding the divested oncology assets, grew slightly, and that BioReference reduced its workforce by roughly 29% from the prior year to about 1,400 full-time employees as part of broader operational efficiency initiatives. Management said these changes significantly improved margins and underpin ...